Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer

被引：0
|
作者：
Seruga, B. [1 ]
Gan, H. K. [1 ]
Knox, J. J. [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Div Hematol & Med Oncol, Toronto, ON, Canada
来源：
CURRENT ONCOLOGY | 2009年 / 16卷
关键词：
Sunitinib; sorafenib; temsirolimus; toxicity; side effects; management; RENAL-CELL CARCINOMA; TYROSINE KINASE INHIBITOR; CARDIAC-HYPERTROPHY; INTERFERON-ALPHA; DOUBLE-BLIND; SUNITINIB; HYPOTHYROIDISM; HYPERTENSION; MANAGEMENT; SAFETY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment.
引用
收藏
页码：S54 / S61
页数：8
相关论文
共 50 条
  • [1] Toxicities of Targeted Therapy and Their Management in Kidney Cancer
    Di Lorenzo, Giuseppe
    Porta, Camillo
    Bellmunt, Joaquim
    Sternberg, Cora
    Kirkali, Ziya
    Staehler, Michael
    Joniau, Steven
    Montorsi, Francesco
    Buonerba, Carlo
    EUROPEAN UROLOGY, 2011, 59 (04) : 526 - 540
  • [2] Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma
    Ryan, Christopher W.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (01) : 43 - 55
  • [3] Advanced kidney cancer: treating the elderly
    Zustovich, Fable
    Novara, Giacomo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (12) : 1389 - 1398
  • [4] Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction
    Gupta, Sachin
    Parsa, Venkata
    Heilbrun, Lance K.
    Smith, Daryn W.
    Dickow, Brenda
    Heath, Elisabeth
    Vaishampayan, Ulka
    ANTI-CANCER DRUGS, 2011, 22 (08) : 794 - 800
  • [5] Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines
    Escudier, Bernard
    Joly, Florence
    Soria, Jean-Charles
    BULLETIN DU CANCER, 2011, 98 : S3 - S6
  • [6] The therapy of kidney cancer with biomolecular drugs
    Di Lorenzo, G.
    Buonerba, C.
    Biglietto, M.
    Scognamiglio, F.
    Chiurazzi, B.
    Riccardi, F.
    Carteni, G.
    CANCER TREATMENT REVIEWS, 2010, 36 : S16 - S20
  • [7] Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update
    North, Scott A.
    Basappa, Naveen
    Basiuk, Joan
    Bjarnason, Georg
    Breau, Rodney
    Canil, Christina
    Heng, Daniel
    Jewett, Michael A. S.
    Kapoor, Anil
    Kollmannsberger, Christian
    Potvin, Kylea
    Reaume, M. Neil
    Ruether, J. Dean
    Venner, Peter
    Wood, Lori
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2015, 9 (5-6): : 164 - 170
  • [8] Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update
    North, Scott
    Basappa, Naveen
    Bjarnason, Georg
    Blais, Normand
    Canil, Christina
    Heng, Daniel
    Knox, Jennifer
    Reaume, Neil
    Ruether, Dean
    Soulieres, Denis
    Zalewski, Pawel
    Black, Peter
    Breau, Rodney
    Jewett, Michael
    Kapoor, Anil
    Lattouf, Jean-Baptiste
    Moore, Ronald
    Rendon, Ricardo
    Todd, Gerald
    Pituskin, Edith
    Gedye, Craig
    Wood, Lori
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2013, 7 (7-8): : 238 - 243
  • [9] Survival outcomes for advanced kidney cancer patients in the era of targeted therapies
    Rao, Arpit
    Wiggins, Charles
    Lauer, Richard C.
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (09)
  • [10] A comparison of drug resistances of targeted drugs for advanced renal cell cancer approved by the Food and Drug Administration: A meta-analysis of randomized clinical trials
    Guo, Ming
    Cao, Yunsong
    Yang, Jingzhe
    Zhang, Jingfeng
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (05) : 109 - 115
12345